Recent research highlighted the contribution of extracellular matrix, and particularly of ADAMTS proteases, in immune regulation. Now, our work with melanoma and mammary tumor models revealed that tumor blockade induced by the lack of Adamts1 led to an increased vascular deposition of its substrate, the basement membrane glycoprotein NIDOGEN-1 (NID1). Significantly, the overexpression of NID1 in the melanoma syngeneic model also blocked tumor progression, disclosing an overlapping phenotype with the absence of Adamts1. These tumors showed important alterations in their immune infiltrates, emphasizing an enhanced presence of antitumorigenic macrophages and a global inflammatory landscape. We corroborated in vitro that full length NID1, but not its fragments, promoted an M1-like macrophage polarization, mainly mediated by the αvβ3 integrin. Significantly, the projection of RNA-seq from our tumor models to two large human melanoma datasets allowed us to discover a new gene signature associated with good prognosis and the abundance of M1-like macrophages. These results support NID1 as a novel tumor suppressor with immunomodulatory properties, and unveil the existence of key oncological drivers in the extracellular scenario.
Loss of the extracellular protease ADAMTS1 reveals an antitumorigenic program involving the action of NIDOGEN-1 on macrophage polarization.
细胞外蛋白酶 ADAMTS1 的缺失揭示了一种抗肿瘤程序,该程序涉及 NIDOGEN-1 对巨噬细胞极化的作用
阅读:22
作者:Caracuel-Peramos Rita, RodrÃguez-Baena Francisco Javier, Redondo-GarcÃa Silvia, Villatoro-GarcÃa Juan Antonio, GarcÃa-Muñoz Ana, Peris-Torres Carlos, Plaza-Calonge MarÃa Del Carmen, Rubio-Gayarre Alba, López-Millán Belén, Ricciardelli Carmela, Russell Darryl L, Carmona-Sáez Pedro, RodrÃguez-Manzaneque Juan Carlos
| 期刊: | Oncoimmunology | 影响因子: | 6.300 |
| 时间: | 2025 | 起止号: | 2025 Dec;14(1):2508057 |
| doi: | 10.1080/2162402X.2025.2508057 | 研究方向: | 肿瘤 |
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。
